{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T14:57:28Z","timestamp":1778338648458,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T00:00:00Z","timestamp":1625270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.abd.2021.03.006","type":"journal-article","created":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T00:54:47Z","timestamp":1626483287000},"page":"551-557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Evaluation of the level of serum Interleukins (IL-2, IL-4, IL-15 andIL-17) and its relationship with disease severity in patients with alopecia areata"],"prefix":"10.1016","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1413-9436","authenticated-orcid":false,"given":"\u00d6zge","family":"A\u015fk\u0131n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9170-4262","authenticated-orcid":false,"given":"Sera Nur","family":"Y\u00fccesoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5471-8606","authenticated-orcid":false,"given":"Erkam","family":"Co\u015fkun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5140-1926","authenticated-orcid":false,"given":"Burhan","family":"Engin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2239-9430","authenticated-orcid":false,"given":"Server","family":"Serdaro\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2021.03.006_bib0005","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2174\/187221311795399291","article-title":"Alopecia areata","volume":"5","author":"Hon","year":"2011","journal-title":"Recent Pat Inflamm Allergy Drug Discov."},{"key":"10.1016\/j.abd.2021.03.006_bib0010","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s12016-017-8620-9","article-title":"Alopecia Areata: a Comprehensive Review of Pathogenesis and Management","volume":"54","author":"Tr\u00fceb","year":"2018","journal-title":"Clin Rev Allergy Immunol."},{"key":"10.1016\/j.abd.2021.03.006_bib0015","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","article-title":"National Alopecia Areata Foundation. Alopecia areata investigational assessment guidelines--Part II. National Alopecia Areata Foundation","volume":"51","author":"Olsen","year":"2004","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2021.03.006_bib0020","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature09114","article-title":"Genome-wide association study in alopecia areata implicates both innate and adaptive immunity","volume":"466","author":"Petukhova","year":"2010","journal-title":"Nature."},{"key":"10.1016\/j.abd.2021.03.006_bib0025","first-page":"751","article-title":"Alopecia areata: Part 1: pathogenesis, diagnosis, and prognosis","volume":"61","author":"Spano","year":"2015","journal-title":"Can Fam Physician."},{"key":"10.1016\/j.abd.2021.03.006_bib0030","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1046\/j.1365-2230.2002.01077.x","article-title":"Epidemiology and genetics of alopecia areata","volume":"27","author":"McDonagh","year":"2002","journal-title":"Clin Exp Dermatol."},{"key":"10.1016\/j.abd.2021.03.006_bib0035","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/14712598.2016.1188076","article-title":"A novel therapeutic paradigm for patients with extensive alopecia areata","volume":"16","author":"Renert-Yuval","year":"2016","journal-title":"Expert Opin Biol Ther."},{"key":"10.1016\/j.abd.2021.03.006_bib0040","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/1203475418824079","article-title":"The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature","volume":"23","author":"Crowley","year":"2019","journal-title":"J Cutan Med Surg."},{"key":"10.1016\/j.abd.2021.03.006_bib0045","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat Biotechnol."},{"key":"10.1016\/j.abd.2021.03.006_bib0050","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J Immunol."},{"key":"10.1016\/j.abd.2021.03.006_bib0055","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000497166","article-title":"Psychological Profile and Quality of Life of Patients with Alopecia Areata","volume":"5","author":"V\u00e9lez-Mu\u00f1iz","year":"2019","journal-title":"Skin Appendage Disord."},{"key":"10.1016\/j.abd.2021.03.006_bib0060","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/928030","article-title":"Cytokines and other mediators in alopecia areata","volume":"2010","author":"Gregoriou","year":"2010","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.abd.2021.03.006_bib0065","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/bjd.16808","article-title":"Alopecia areata: a review of disease pathogenesis","volume":"179","author":"Rajabi","year":"2018","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2021.03.006_bib0070","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev.immunol.26.021607.090357","article-title":"The biology of interleukin-2","volume":"26","author":"Malek","year":"2008","journal-title":"Annu Rev Immunol."},{"key":"10.1016\/j.abd.2021.03.006_bib0075","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000486462","article-title":"Serum Levels of Interleukin-2 in Patients with Alopecia Areata: Relationship with Clinical Type and Duration of the Disease","volume":"4","author":"Kasumagi\u0107-Halilovic","year":"2018","journal-title":"Skin Appendage Disord."},{"key":"10.1016\/j.abd.2021.03.006_bib0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cytogfr.2016.04.002","article-title":"Interleukin-4 receptor signaling and its binding mechanism: A therapeutic insight from inhibitors tool box","volume":"32","author":"Ul-Haq","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.abd.2021.03.006_bib0085","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.gene.2013.05.086","article-title":"The association between Interleukin (IL)-4 gene intron 3 VNTR polymorphism and alopecia areata (AA) in Turkish population","volume":"527","author":"Kalkan","year":"2013","journal-title":"Gene."},{"key":"10.1016\/j.abd.2021.03.006_bib0090","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cytogfr.2016.06.001","article-title":"Interleukin 15: A key cytokine for immunotherapy","volume":"31","author":"Patidar","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.abd.2021.03.006_bib0095","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4103\/ijt.ijt_80_18","article-title":"Serum Interleukin-15 is a Marker of Alopecia Areata Severity","volume":"11","author":"Ebrahim","year":"2019","journal-title":"Int J Trichology."},{"key":"10.1016\/j.abd.2021.03.006_bib0100","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/ni.3742","article-title":"Interleukin 17 is a chief orchestrator of immunity","volume":"18","author":"Veldhoen","year":"2017","journal-title":"Nat Immunol."},{"key":"10.1016\/j.abd.2021.03.006_bib0105","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/ijd.12994","article-title":"Serum level of interleukin-17A in patients with alopecia areata and its relationship to age","volume":"55","author":"El-Morsy","year":"2016","journal-title":"Int J Dermatol."},{"key":"10.1016\/j.abd.2021.03.006_bib0110","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/jocd.12664","article-title":"Correlation between serum IL-17A level and SALT score in patients with alopecia areata before and after NB-UVB therapy","volume":"17","author":"Morsy","year":"2018","journal-title":"J Cosmet Dermatol."},{"key":"10.1016\/j.abd.2021.03.006_bib0115","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jdv.14775","article-title":"Role of T helper 17 cells and T regulatory cells in alopecia areata: comparison of lesion and serum cytokine between controls and patients","volume":"32","author":"Loh","year":"2018","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2021.03.006_bib0120","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00403-018-1823-y","article-title":"IL-17 inhibition: is it the long-awaited savior for alopecia areata?","volume":"310","author":"Ramot","year":"2018","journal-title":"Arch Dermatol Res."},{"key":"10.1016\/j.abd.2021.03.006_bib0125","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/jidsymp.2015.41","article-title":"Current Treatments for Alopecia Areata","volume":"17","author":"Hordinsky","year":"2015","journal-title":"J Investig Dermatol Symp Proc."},{"key":"10.1016\/j.abd.2021.03.006_bib0130","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/1346-8138.14986","article-title":"Janus kinase inhibitors: An innovative treatment for alopecia areata","volume":"46","author":"Park","year":"2019","journal-title":"J Dermatol."},{"key":"10.1016\/j.abd.2021.03.006_bib0135","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2021.03.006_bib0140","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Crispin","year":"2016","journal-title":"JCI Insight."},{"key":"10.1016\/j.abd.2021.03.006_bib0145","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1001\/jamadermatol.2017.0001","article-title":"Treatment of Alopecia Areata With Tofacitinib","volume":"153","author":"Ibrahim","year":"2017","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.abd.2021.03.006_bib0150","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1684\/ejd.2019.3668","article-title":"Low-dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost-saving regimen","volume":"29","author":"Chen","year":"2019","journal-title":"Eur J Dermatol."},{"key":"10.1016\/j.abd.2021.03.006_bib0155","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12844","article-title":"Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients","volume":"32","author":"Serdaro\u011flu","year":"2019","journal-title":"Dermatol Ther."},{"key":"10.1016\/j.abd.2021.03.006_bib0160","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/jdv.15937","article-title":"Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis","volume":"34","author":"Guo","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059621001744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059621001744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T23:38:42Z","timestamp":1759793922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059621001744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0365059621001744"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2021.03.006","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the level of serum Interleukins (IL-2, IL-4, IL-15 andIL-17) and its relationship with disease severity in patients with alopecia areata","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2021.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedade Brasileira de Dermatologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}